• Explore /
  • Poster
  • / Relapse-free survial and target identification to enhance response with neoadjuvant and adjuvant dabrafenib + trametinib (D+T) treatment compared to standard-of-care (SOC) surgery in patients (pts) with high-risk resectable BRAF-mutant metastatic melanoma.

Relapse-free survial and target identification to enhance response with neoadjuvant and adjuvant dabrafenib + trametinib (D+T) treatment compared to standard-of-care (SOC) surgery in patients (pts) with high-risk resectable BRAF-mutant metastatic melanoma.

Abstract Poster

Authors

null

Jennifer Ann Wargo

The University of Texas MD Anderson Cancer Center, Houston, TX

Jennifer Ann Wargo , Rodabe Navroze Amaria , Peter A. Prieto , Miles Cameron Andrews , Michael T. Tetzlaff , Phillip Andrew Futreal , Patrick Hwu , Wen-Jen Hwu , Isabella Claudia Glitza , Hussein Abdul-Hassan Tawbi , Janice N. Cormier , Jeffrey Edwin Lee , Sapna Pradyuman Patel , Lauren Simpson , Elizabeth M. Burton , Roland L. Bassett Jr., Merrick I. Ross , Jeffrey E. Gershenwald , Michael A. Davies , Scott Eric Woodman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Local-Regional Disease

Clinical Trial Registration Number

NCT02231775

Citation

J Clin Oncol 35, 2017 (suppl; abstr 9587)

DOI

10.1200/JCO.2017.35.15_suppl.9587

Abstract #

9587

Poster Bd #

195

Abstract Disclosures

Similar Posters

First Author: Jennifer Ann Wargo

First Author: Tarin Hennegan

First Author: Rodabe Navroze Amaria

First Author: Teresa M. Petrella